CACIPLIQ20 (RGTA)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for CACIPLIQ20 (RGTA).
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| CACIPLIQ20 (RGTA) | Tissue Repair | Regenerative Biologic | Phase 3 | 0 | ||||
| Botulinum Toxin Injection After Sternotomies to Improve Scar Aspect and Impact | University Hospital, Bordeaux | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
| — |
| — |
| — |
| — |
| — |
| Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars | National Skin Centre | — | Phase 2 | — | — | — | — | — |